Intracellular proteins displayed on the surface of tumor cells as targets for therapeutic intervention with antibody-related agents

Cancer Genomics and Proteomics

Volumn 8, Issue 2, 2011, Pages 49-64

  Weidle, Ulrich H ^a   Maisel, Daniela ^a   Klostermann, Stefan ^a   Schiller, Christian ^b   Weiss, Elisabeth H ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Actin; Cytokeratin(s); Estrogen receptor; Feto acinar pancreatic protein; Glucose related protein 78; Heat shock proteins 70 and 90; Ingenuity pathway analysis (IPA); Nucleolin; Nucleosomes; Review; Tumor specific antigens; Vimentin

Indexed keywords

ACTIN; ANTIBODY; BORTEZOMIB; CELL PROTEIN; CYTOKERATIN; CYTOKERATIN 1; CYTOKERATIN 8; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA VARIANT 36; FETO ACINAR PANCREATIC PROTEIN; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LETROZOLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 16D10; MONOCLONAL ANTIBODY J28; NUCLEOLIN; PRITUMUMAB; TAMOXIFEN; UNCLASSIFIED DRUG; VIMENTIN;

ASTROCYTOMA; BREAST CANCER; CELL SURFACE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; GLIOBLASTOMA; HUMAN; NONHUMAN; NUCLEOSOME; REVIEW; TUMOR CELL;

EID: 79955046674     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
2. Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-1081, 2009
3. Horváth I, Multhoff G, Sonnleitner A and Vígh L: Membrane-associated stress proteins: more than simply chaperones. Biochim Biophys Acta 1778: 1653-1664, 2008.
4. Ferrarini M, Heltai S, Zocchi MR and Rugarli C: Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51: 613-619, 1992.
5. Piselli P, Vendetti S, Poccia F, Cicconi R, Mattei M, Bolognesi A, Stirpe F and Colizzi V: In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells. J Biol Regul Homeost Agents 9: 55-62, 1995.
6. Tamura Y, Tsuboi N, Sato N and Kikuchi K: 70 kDa Heat Shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity. J Immunol 151: 5516-5524, 1993. (Pubitemid 23332361)
7. Multhoff G, Botzler C, Wiesnet M, Müller E, Meier T, Wilmanns W and Issels RD: A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 61: 272-279, 1995.
8. Naaby-Hansen S and Herr JC: Heat-shock proteins on the human sperm surface. J Reprod Immunol 84: 32-40, 2010.
9. Multhoff G: Activation of natural killer cells by heat-shock protein 70. 2002. Int J Hyperthermia 25: 169-175, 2009.
10. Multhoff G, Pfister K, Gehrmann M, Hantschel M, Gross C, Hafner M and Hiddemann W: A 14-mer HSP70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones 6: 337-344, 2001. (Pubitemid 33123486)
11. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA and Multhoff G: Heat-shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 65: 5238-5247, 2005. (Pubitemid 40827334)
12. Gehrmann M, Liebisch G, Schmitz G, Anderson R, Steinern C, De Maio A, Pockley G and Multhoff G: Tumor-specific HSP70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS One 3: e1925, 2008.
13. Stangl S, Gehrmann M, Dressel R, Alves F, Dullin C, Themelis G, Ntziachristos V, Staeblein E, Walch A, Winkelmann I and Multhoff G: In vivo imaging of CT26 mouse tumors by using cmHSP70.1 monoclonal antibody. J Cell Mol Med 14: 992-1002, 2010.
14. Zettlitz KA, Seitter J, Müller D and Kontermann RE: Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (HSP70). Mol Biotechnol 46: 265-278, 2010
15. Friedrich L, Stangl S, Hahne H, Küster B, Köhler P, Multhoff G and Skerra A: Bacterial production and functional characterization of the Fab fragment of the murine IgG1/lambda monoclonal antibody cmHSP70.1, a reagent for tumour diagnostics. Protein Eng Des Sel 23: 161-168, 2010.
16. Trepel J, Mollapour M, Giaccone G and Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10, 537-549, 2010.
17. Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G and Luo Y: The regulatory mechanism of HSP90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci USA 106: 21288-21293, 2009.
18. Song X and Luo Y: The regulatory mechanism of HSP90alpha secretion from endothelial cells and its role in angiogenesis during wound healing. Biochem Biophys Res Commun 398: 111-117, 2010.
19. Ullrich SJ, Robinson EA, Law LW, Willingham M and Appella E: A mouse tumor-specific transplantation antigen is a heat-shock-related protein. Proc Natl Acad Sci USA 83: 3121-3125, 1986. (Pubitemid 16042988)
20. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W and Vogt T: Induction of HSP90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 13: 27-32, 2004. (Pubitemid 38165435)
21. Ferrarini M, Heltai S, Zocchi MR and Rugarli C: Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51: 613-619, 1992.
22. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL and Jay DG: Functional proteomic screens reveal an essential extracellular role for HSP90 alpha in cancer cell invasiveness. Nat Cell Biol 6: 507-514, 2004. (Pubitemid 38786593)
23. Cid C, Regidor I, Poveda PD and Alcazar A: Expression of heat -shock protein 90 at the cell surface in human neuroblastoma cells. Cell Stress Chaperones 14: 321-327, 2009.
24. Sapozhnikov AM, Ponomarev ED, Tarasenko TN and Telford WG: Spontaneous apoptosis and expression of cell surface heat-shock proteins in cultured EL-4 lymphoma cells. Cell Prolif 32: 363-378, 1999. (Pubitemid 30050405)
25. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S and Dhodapkar MV: Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat-shock protein 90 on dying tumor cells: therapeutic implications. Blood 109: 4839-4845, 2007. (Pubitemid 46827780)
26. Sidera K, Samiotaki M, Yfanti E, Panayotou G and Patsavoudi E: Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem 279: 45379-45388, 2004. (Pubitemid 39491521)
27. Picard D: HSP90 invades the outside. Nat Cell Biol 6: 479-480, 2004.
28. McCready J, Sims JD, Chan D and Jay DG: Secretion of extracellular HSP90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 10: 294, 2010.
29. Stellas D, Karameris A and Patsavoudi E: Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin Cancer Res 13: 1831-1838, 2007.
30. Li W, Li Y, Guan S, Fan J, Cheng CF, Bright AM, Chinn C, Chen M and Woodley DT: Extracellular heat-shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J 26: 1221-1233, 2007. (Pubitemid 46398702)
31. Basu S, Binder RJ, Ramalingam T and Srivastava PK: CD91 is a common receptor for heat-shock proteins gp96, HSP90, HSP70, and calreticulin. Immunity 14: 303-313, 2001. (Pubitemid 32289294)
32. Triantafilou M and Triantafilou K: Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide. Biochem Soc Trans 32: 636-639, 2004. (Pubitemid 39120403)
33. Sidera K, Gaitanou M, Stellas D, Matsas R and Patsavoudi E: A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 283: 2031-2041, 2008.
34. Sidera K and Patsavoudi E: Extracellular HSP90: conquering the cell surface. Cell Cycle 7: 1564-1568, 2008. (Pubitemid 351881322)
35. Stellas D, El Hamidieh A and Patsavoudi E: Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11: 51, 2010.
36. Tsutsumi S and Neckers L: Extracellular heat-shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 98: 1536-1539, 2007. (Pubitemid 47308447)
37. Li J and Lee AS: Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 6: 45-54, 2006.
38. Lee AS and Hendershot LM: ER stress and cancer. Cancer Biol Ther 5: 721-722, 2006. (Pubitemid 44775123)
39. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W and Pasqualini R: Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6: 275-284, 2004. (Pubitemid 39222040)
40. Rauschert N, Brändlein S, Holzinger E, Hensel F, Müller-Hennelink HK and Vollmers HP: A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest 88: 375-386, 2008. (Pubitemid 351432774)
41. Misra UK, Mowery Y, Kaczowka S and Pizzo SV: Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. MoI Cancer Ther 8: 1350-1362, 2009.
42. + exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. J Biol Chem 280: 27173-21178, 2005.
43. Gonzalez-Gronow M, Selim MA, Papalas J and Pizzo SV: GRP78: a multifunctional receptor on the cell surface. Antioxid Redox Signal 11: 2299-2306, 2009.
44. Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N and Oku N: Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int J Cancer 127: 2685-2698, 2010.
45. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR and Rangnekar VM: The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138: 377-388, 2009.
46. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R and Rangnekar VM: Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 23: 5516-5525, 2003. (Pubitemid 36951320)
47. Schwarze S and Rangnekar VM: Targeting plasma membrane GRP78 for cancer growth inhibition. Cancer Biol Ther 9: 153-155, 2010.
48. Shrestha-Bhattarai T and Rangnekar VM: Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene 29: 3873-3880, 2010.
49. Zhao Y, Burikhanov R, Qiu S, Lele SM, Jennings CD, Bondada S, Spear B and Rangnekar VM: Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res 67: 9276-9285, 2007.
50. Pohle T, Brändlein S, Ruoff N, Müller-Hermelink HK and Vollmers HP: Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res 64: 3900-3906, 2004.
51. Brändlein S, Rauschert N, Rasche L, Dreykluft A, Hensel F, Conzelmann E, Müller-Hermelink HK and Vollmers HP: The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein. Mol Cancer Ther 6: 326-333, 2007.
52. Fuchs E and Weber K: Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63: 345-382, 1994.
53. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal Transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 185: 191-203, 2007. (Pubitemid 46957486)
54. Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, Luo X, Lazar A, Dicker A, Mills GB, Hung MC and Lev D: Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 30: 457-470, 2011
55. Bhattacharya R, Gonzalez AM, Debiase PJ, Trejo HE, Goldman RD, Flitney FW and Jones JC: Recruitment of vimentin to the cell surface by beta3 integrin and plectin mediates adhesion strength. J Cell Sci 122: 1390-1400, 2009.
56. Glassy MC and Hagiwara H: Summary analysis of the preclinical and clinical results of brain tumor patients treated with pritumumab. Hum Antibodies 18: 127-137, 2009.
57. Aotsuka Y and Hagiwara H: Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur J Cancer Clin Oncol 24: 829-838, 1988.
58. Gires O, Mack B, Rauch J and Matthias C: CK8 conelates with malignancy in leukoplakia and carcinomas of the head and neck. Biochem Biophys Res Commun 343: 252-259, 2006.
59. Hembrough TA, Vasudevan J, Allietta MM, Glass WF 2nd and Gonias SL: A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci 108: 1071-1082, 1995.
60. Hembrough TA, Li L and Gonias SL: Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem 271: 25684-25691, 1996. (Pubitemid 26337950)
61. Borup-Christensen P, Erb K, Jensenius JC, Nielsen B and Svehag SE: Human-human hybridomas for the study of antitumor immune response in patients with colorectal cancer. Int J Cancer 37: 683-688, 1986. (Pubitemid 16042059)
62. Ditzel HJ, Garrigues U, Andersen CB, Larsen MK, Garrigues HJ, Svejgaard A, Hellström I, Hellström KE and Jensenius JC: Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Proc Natl Acad Sci USA 94: 8110-8115, 1997. (Pubitemid 27343785)
63. Wells MJ, Hatton MW, Hewlett B, Podor TJ, Sheffield WP and Blajchman MA: Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes. J Biol Chem 272: 28574-28581, 1997. (Pubitemid 27517810)
64. Mahdi F, Shariat-Madar Z, Todd RF 3rd, Figueroa CD and Schmaier AH: Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 97: 2342-2350, 2001. (Pubitemid 32291480)
65. Motta G, Shariat-Madar Z, Mahdi F, Sampaio CA and Schmaier AH: Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix. Thromb Haemost 86: 840-847, 2001. (Pubitemid 32834195)
66. Furmaniak-Kazmierczak E, Nesheim ME and Côté GP: Coagulation factor Va is an actin filament binding and cross-linking protein. Biochem Cell Biol 73: 105-112, 1995.
67. Moroianu J, Fett JW, Riordan JF and Vallee BL: Actin is a surface component of calf pulmonary artery endothelial cells in culture. Proc Natl Acad Sci USA 90: 3815-3819, 1993. (Pubitemid 23134116)
68. Dudani AK and Ganz PR: Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Br J Haematol 95: 168-178, 1996. (Pubitemid 26340247)
69. Dubernard V, Faucher D, Launay JM and Legrand C: Identification of the cytoskeletal protein alpha-actinin as a platelet thrombospondin-binding protein. FEBS Lett 364: 109-114, 1995.
70. Hajjar KA, Guevara CA, Lev E, Dowling K and Chacko J: Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface. Essential role of endonexin repeat 2. J Biol Chem 271: 21652-21659, 1996. (Pubitemid 26293036)
71. Srivastava M and Pollard HB: Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 13: 1911-1922, 1999.
72. Ginisty H, Sicard H, Roger B and Bouvet P: Structure and functions of nucleolin. J Cell Sci 112: 761-772, 1999.
73. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P and Ruoslahti E: Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 163: 871-878, 2003. (Pubitemid 37517893)
74. Shi H, Huang Y, Zhou H, Song X, Yuan S, Fu Y and Luo Y: Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 110: 2899-2906, 2007. (Pubitemid 350006943)
75. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286, 2007.
76. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y and Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361: 79-84, 2007. (Pubitemid 47102270)
77. Huang Y, Shi H, Zhou H, Song X, Yuan S and Luo Y: The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 107: 3564-3571, 2006.
78. Yuan S, Fu Y, Wang X, Shi H, Huang Y, Song X, Li L, Song N and Luo Y: Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis. FASEB J 22: 2809-2820, 2008.
79. 2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65: 3656-3663, 2005. (Pubitemid 40616342)
80. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M and Gustafsson JA: Update on estrogen signaling. FEBS Lett 546: 17-24, 2003. (Pubitemid 36789762)
81. Kong EH, Pike AC and Hubbard RE: Structure and mechanism of the oestrogen receptor. Biochem Soc Trans 31: 56-59, 2003.
82. Pietras RJ and Szego CM: Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265: 69-72, 1977. (Pubitemid 8004314)
83. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-1027, 2005. (Pubitemid 41383424)
84. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103: 9063-9068, 2006. (Pubitemid 43902533)
85. Zou Y, Ding L, Coleman M and Wang Z: Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett 583: 1368-1374, 2009.
86. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Wang Z and Xie Y: Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27: 3423-3429, 2009.
87. Lee LM, Cao J, Deng H, Chen P, Gatalica Z and Wang ZY: ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 28: 479-483, 2008.
88. Lin SL, Yan LY, Liang XW, Wang ZB, Wang ZY, Qiao J, Schatten H and Sun QY: A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol 7: 102, 2009.
89. Benkoël L, Bernard JP, Payan-Defais MJ, Crescence L, Franceschi C, Delmas M, Ouaissi M, Sastre B, Sahel J, Benoliel AM, Bongrand P, Silvy F, Gauthier L, Romagné F, Lombardo D and Mas E: Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues. Mol Cancer Ther 8: 282-291, 2009.
90. Lombardo D, Fauvel J and Guy O: Studies on the substrate specificity of a carboxyl ester hydrolase from human pancreatic juice. I. Action on carboxyl esters, glycerides and phospholipids. Biochim Biophys Acta 611: 136-146, 1980.
91. Lombardo D and Guy O: Studies on the substrate specificity of a carboxyl ester hydrolase from human pancreatic juice. II. Action on cholesterol esters and lipid-soluble vitamin esters. Biochim Biophys Acta 611: 147-155, 1980.
92. Mas E, Abouakil N, Roudani S, Miralles F, Guy-Crotte O, Figarella C, Escribano MJ and Lombardo D: Human fetoacinar pancreatic protein: an oncofetal glycoform of the normally secreted pancreatic bile-salt-dependent lipase. Biochem J 289: 609-615, 1993. (Pubitemid 23042078)
93. Albers GH, Escribano MJ, Gonzalez M, Mulliez N and Nap M: Fetoacinar pancreatic protein in the developing human pancreas. Differentiation 34: 210-215, 1987.
94. Pasqualini E, Caillol N, Panicot L, Mas E, Lloubes R and Lombardo D: Molecular cloning of the oncofetal isoform of the human pancreatic bile salt-dependent lipase. J Biol Chem 273: 28208-28218, 1998. (Pubitemid 28496119)
95. Escribano MJ and Imperial S: Purification and molecular characterization of FAP, a feto-acinar protein associated with the differentiation of human pancreas. J Biol Chem 264: 21865-21871, 1989.
96. Sadoulet MO, Franceschi C, Aubert M, Silvy F, Bernard JP, Lombardo D and Mas E: Glycoengineering of alphaGal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope. Glycobiology 17: 620-630, 2007. (Pubitemid 47062705)
97. Panicot-Dubois L, Aubert M, Franceschi C, Mas E, Silvy F, Crotte C, Bernard JP, Lombardo D and Sadoulet MO: Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts. Neoplasia 6: 713-724, 2004. (Pubitemid 40041489)